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Cancers are mainly caused by somatic genomic alterations (SGAs) that perturb cellular
signaling systems and eventually activate oncogenic processes. Therefore, understanding
the functional impact of SGAs is a fundamental task in cancer biology and precision on-
cology. Here, we present a deep neural network model with encoder-decoder architecture,
referred to as genomic impact transformer (GIT), to infer the functional impact of SGAs
on cellular signaling systems through modeling the statistical relationships between SGA
events and differentially expressed genes (DEGs) in tumors. The model utilizes a multi-head
self-attention mechanism to identify SGAs that likely cause DEGs, or in other words, differ-
entiating potential driver SGAs from passenger ones in a tumor. GIT model learns a vector
(gene embedding) as an abstract representation of functional impact for each SGA-affected
gene. Given SGAs of a tumor, the model can instantiate the states of the hidden layer, pro-
viding an abstract representation (tumor embedding) reflecting characteristics of perturbed
molecular/cellular processes in the tumor, which in turn can be used to predict multiple
phenotypes. We apply the GIT model to 4,468 tumors profiled by The Cancer Genome Atlas
(TCGA) project. The attention mechanism enables the model to better capture the statis-
tical relationship between SGAs and DEGs than conventional methods, and distinguishes
cancer drivers from passengers. The learned gene embeddings capture the functional simi-
larity of SGAs perturbing common pathways. The tumor embeddings are shown to be useful
for tumor status representation, and phenotype prediction including patient survival time
and drug response of cancer cell lines.∗
Keywords: Neural networks; Knowledge representation; Gene regulatory networks; Cancer.
1. Introduction
Cancer is mainly caused by the activation of oncogenes or deactivation of tumor suppressor
genes (collectively called “driver genes”) as results of somatic genomic alterations (SGAs),1
including somatic mutations (SMs),2,3 somatic copy number alterations (SCNAs),4,5 DNA
structure variations (SVs),6 and epigenetic changes.7 Precision oncology relies on the capa-
bility of identifying and targeting tumor-specific aberrations resulting from driver SGAs and
∗Supplemental information (SI), GIT model, pre-processed TCGA data, and gene embeddings are
available at https://github.com/yifengtao/genome-transformer.
c© 2019 The Authors. Open Access chapter published by World Scientific Publishing Company and
distributed under the terms of the Creative Commons Attribution Non-Commercial (CC BY-NC)
4.0 License.
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their effects on molecular and cellular phenotypes. However, our knowledge of driver SGAs
and cancer pathways remains incomplete. Particularly, it remains a challenge to determine
which SGAs (among often hundreds) in a specific tumor are drivers, which cellular signals or
biological processes a driver SGA perturbs, and which molecular/cellular phenotypes a driver
SGA affects.
Current methods for identifying driver genes mainly concentrate on identifying genes that
are mutated at a frequency above expectation, based on the assumption that mutations in
these genes may provide oncogenic advantages and thus are positively selected.8,9 Some works
further focus on the mutations perturbing conserved (potentially functional) domains of pro-
teins as indications they may be driver events.10,11 However, these methods do not provide
any information regarding the functional impact of enriched mutations on molecular/cellular
phenotypes of cells. Without the knowledge of functional impact, it is difficult to further de-
termine whether an SGA will lead to specific molecular, cellular and clinical phenotypes, such
as response to therapies. What’s more, while both SMs and SCNAs may activate/deactivate a
driver gene, there is no well-established frequency-based method that combines different types
of SGAs to determine their functional impact.
Conventionally, an SGA event perturbing a gene in a tumor is represented as a “one-hot”
vector spanning gene space, in which the element corresponding to the perturbed gene is set
to “1”. This representation simply indicates which gene is perturbed, but it does not reflect
the functional impact of the SGA, nor can it represent the similarity of distinct SGAs that
perturb a common signaling pathway. We conjecture that it is possible to represent an SGA
as a low-dimensional vector, in the same manner as the “word embedding”12–14 in the natural
language processing (NLP) field, such that the representation reflects the functional impact
of a gene on biological systems, and genes sharing similar functions should be closely located
in such embedding space. Here the “similar function” is broadly defined, e.g., genes from the
same pathway or of the same biological process.15 Motivated by this, we propose a scheme for
learning “gene embeddings” for SGA-affected genes, i.e., a mapping from individual genes to
low-dimensional vectors of real numbers that are useful in multiple prediction tasks.
Based on the assumption that SGAs perturbing cellular signaling systems often eventually
lead to changes in gene expression,16 we introduce an encoder-decoder architecture neural
network model called “genomic impact transformer” (GIT) to predict DEGs and detect po-
tential cancer drivers with the supervision of DEGs. While deep learning models are being
increasingly used to model different bioinformatics problems,17,18 to our knowledge there are
few studies using the neural network to model the relationships between SGAs and molec-
ular/cellular phenotypes in cancers. The proposed GIT model has the following innovative
characteristics: (1) The encoder part of the transformer19 first uses SGAs observed in a tumor
as inputs, maps each SGA into a gene embedding representation, and combines gene embed-
dings of SGAs to derive a personalized “tumor embedding”. Then the decoder part decodes
and translates the tumor embedding to DEGs. (2) A multi-head self-attention mechanism20,21
is utilized in the encoder, which is a technique widely used in NLP to choose the input features
that significantly influence the output. It differentiates SGAs by assigning different weights to
them so that it can potentially distinguish SGAs that have an impact on DEG from those do
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Fig. 1. (a) Overall architecture of GIT. An example case and its detected drivers are shown. (b)
A two-dimensional demo that shows how attention mechanism combines multiple gene embeddings
of SGAs {eg}mg=1 and cancer type embedding es into a tumor embedding vector et using attention
weights {αg}mg=1. (c) Calculation of attention weights {αg}mg=1 using gene embeddings {eg}mg=1.
not, i.e., detecting drivers from passengers. (3) Pooling inferred weighted impact of SGAs in a
tumor produces a personalized tumor embedding, which can be used as an effective feature to
predict DEGs and other phenotypes. (4) Gene embeddings are pre-trained by a “Gene2Vec”
algorithm and further refined by the GIT, which captures the functional impact of SGAs
on the cellular signaling system. Our results and analysis indicate that above innovative ap-
proaches enable us to derive powerful gene embedding and tumor embedding representations
that are highly informative of molecular, cellular and clinical phenotypes.
2. Materials and methods
2.1. SGAs and DEGs pre-processing
We obtained SGA data, including SMs and SCNAs, and DEGs of 4,468 tumors consisting of
16 cancer types directly from TCGA portal.22 Details available in SI (Sec. S1).
2.2. The GIT neural network
2.2.1. GIT network structure: encoder-decoder architecture
Figure 1a shows the general structure of the GIT model with an overall encoder-decoder
architecture. GIT mimics hierarchically organized cellular signaling system,23,24 in which a
neuron may potentially encode the signal of one or more signaling proteins. When a cellular
signaling system is perturbed by SGAs, it often can lead to changes in measured molecular
phenotypes, such as gene expression changes. Thus, for a tumor t, the set of its SGAs {g}mg=1
is connected to the GIT neural network as observed input (Fig. 1a bottom part squares).
The impact of SGAs is represented as embedding vectors {eg}mg=1, which are further linearly
combined to produce a tumor embedding vector et through an attention mechanism in the
encoder (Fig. 1a middle part). We explicitly represent cancer type s and its influence on
encoding system es of the tumor because tissue type influences which genes are expressed in
cells of specific tissue as well. Finally, the decoder module, which consists of a feed-forward
multi-layer perceptron (MLP),25 transforms the functional impact of SGAs and cancer type
into DEGs of the tumor (Fig. 1a top part).
2.2.2. Pre-training gene embeddings using Gene2Vec algorithm
In this study, we projected the discrete binary representation of SGAs perturbing a gene into a
continuous embedding space, which we call “gene embeddings” of corresponding SGAs, using
a “Gene2Vec” algorithm, based on the assumption of co-occurrence pattern of SGAs in each
tumor, including mutually exclusive patterns of mutations affecting a common pathway.26
These gene embeddings were further updated and fine-tuned by the GIT model with the
supervision of affected DEGs. Algorithm details available in SI (Sec. S2).
2.2.3. Encoder: multi-head self-attention mechanism
To detect the difference of functional impact of SGAs in a tumor, we designed a multi-head
self-attention mechanism (Fig. 1a middle part). For all SGA-affected genes {g}mg=1 and the
cancer type s of a tumor t, we first mapped them to corresponding gene embeddings {eg}mg=1
and a cancer type embedding es from a look-up table E = {eg}g∈G ∩ {es}s∈S , where eg and es
are real-valued vectors. From the implementation perspective, we treated cancer types in the
same way as SGAs, except the attention weight of it is fixed to be “1”. The overall idea of
producing the tumor embedding et is to use the weighted sum of cancer type embedding es
and gene embeddings {eg}mg=1 (Fig. 1b) :
et = 1 · es +
∑
g
αg · eg = 1 · es + α1 · e1 + ...+ αm · em. (1)
The attention weights {αg}mg=1 were calculated by employing multi-head self-attention
mechanism, using gene embeddings of SGAs {eg}mg=1 in the tumor: {αg}mg=1 =
FunctionAttention
(
{eg}mg=1 ;W0,Θ
)
(Fig. 1c). See SI (Sec. S3) for mathematical details. Over-
all we have three parameters {W0,Θ, E} to train in the multi-head attention module using
back-propagation.27 The look-up table {eg}g∈G was initialized with Gene2Vec pre-trained gene
embeddings and refined by GIT here.
2.2.4. Decoder: multi-layer perceptron (MLP)
For a specific tumor t, we fed tumor embedding et into an MLP with one hidden layer as the
decoder, using non-linear activation functions and fully connected layers, to produce the final
predictions yˆ for DEGs y; (Fig. 1a top part):
yˆ = σ(W2 ·ReLU(W1 ·ReLU(et) + b1) + b2). (2)
where ReLU(x) = max(0, x) is rectified linear unit, and σ(x) = (1+exp(−x))−1 is sig-
moid activation function. The output of the decoder and actual values of DEGs were
used to calculate the `2-regularized cross entropy, which was minimized during training:
minW,E,Θ,b CrossEnt(y, yˆ) + `2(W, E ,Θ;λ2), where W = {Wl}2l=0, cross entropy loss defined as
CrossEnt(y, yˆ) = −∑i [(1− yi) log(1− yˆi) + yi log yˆi], and `p regularizer defined as `p(W;λ) =
λ ·∑l ‖Wl‖p , p ∈ {1, 2}.
2.3. Training and evaluation
We utilized PyTorch (https://pytorch.org/) to train, validate and test the Gene2Vec, GIT
(variants) and other conventional models (Lasso and MLPs; Section 3.1). The training, vali-
dation and test sets were split in the ratio of 0.33:0.33:0.33 and fixed across different models.
The hyperparameters were tuned over the training and validation sets to get best F1 scores,
trained on training and validation sets, and finally applied to the test set for evaluation if not
further mentioned below. The models were trained by updating parameters using backpropa-
gation,27 specifically, using mini-batch Adam28 with default momentum parameters. Gene2Vec
used mini-batch stochastic gradient descent (SGD) instead of Adam. Dropout29 and weight
decay (`p-regularization) were used to prevent overfitting. We trained all the models 30 to
42 epochs until they fully converged. The output DEGs were represented as a sparse binary
vector. We utilized various performance metrics including accuracy, precision, recall, and F1
score, where F1 is the harmonic mean of precision and recall. The training and test were re-
peated for five runs get the mean and variance of evaluation metrics. We designed two metrics
in the present work for evaluating the functional similarity among genes sharing similar gene
embedding: “nearest neighborhood (NN) accuracy” and “GO enrichment”. See SI (Sec. S4)
for the definition and meaning of them.
3. Results
3.1. GIT statistically detects real biological signals
Table 1. Performances of GIT (variants) and baseline methods.
Methods Precision Recall F1 score Accuracy
Lasso 59.6±0.05 52.8±0.03 56.0±0.01 74.0±0.02
1 layer MLP 61.9±0.09 50.4±0.17 55.6±0.07 74.7±0.02
2 layer MLP 64.2±0.39 52.0±0.66 57.4±0.28 75.9±0.09
3 layer MLP 64.2±0.37 50.5±0.30 56.5±0.19 75.7±0.13
GIT - can 60.5±0.34 45.8±0.38 52.1±0.29 73.6±0.14
GIT - attn 67.6±0.32 55.3±0.77 60.8±0.35 77.7±0.05
GIT - init 69.8±0.28 54.1±0.37 60.9±0.16 78.3±0.06
GIT 69.5±0.09 57.1±0.18 62.7±0.08 78.7±0.01
The task of GIT is to predict
DEGs (dependent variables) us-
ing SGAs as input (independent
variables). Our results of GIT
performance on both real and
shuffled data demonstrates that
GIT is able to capture real statis-
tical relationships between SGAs
and DEGs from the noisy biolog-
ical data (SI: Sec. S5).
As a comparison, we also
trained and tested the Lasso
(a) (b) (c)
Fig. 2. (a) GO enrichment of vs. number of groups in k -means clustering. (b) t-SNE visualization of
gene embeddings. The different colors represent k -means (40 clusters) clustering labels. An enlarged
inset of a cluster is shown, which contains a set of closely related genes which we refer to “IFN
pathway”. (c) Landscape of attention of SGAs based on attention weights and frequencies.
(multivariate regression with `1-regularization)30 and MLPs25 as baseline prediction models
to predict DEGs based on SGAs. The Lasso model is appealing in our setting because, when
predicting a DEG, it can filter out most of the irrelevant input variables (SGAs) and keep
only the most informative ones, and it is a natural choice in our case where there are 19.8k
possible SGAs. However, in comparison to MLP, it lacks the capability of portraying complex
relationships between SGAs and DEGs. On the other hand, while conventional MLPs have
sufficient power to capture complex relationships–particularly, the neurons in hidden layers
may mimic signaling proteins24–they can not utilize any biological knowledge extracted from
cancer genomics, nor do they explain the signaling process and distinguish driver SGAs. We
employed the precision, recall, F1 score, as well as accuracy to compare GIT and traditional
methods (Table 1: 1st to 4th, and last rows). One can conclude that GIT outperforms all
these other conventional baseline methods for predicting DEGs in all metrics, indicating the
specifically designed structure of GIT is able to soar the performance in the task of predicting
DEGs from SGAs.
In order to evaluate the utility of each module (procedure) in GIT, we conducted ablation
study by removing one module at a time: the cancer type input (“can”), the multi-head self-
attention module (“attn”), and the initialization with pre-trained gene embeddings (“init”).
The impact of each module can be detected by comparing to the full GIT model. All the
modules in GIT help to improve the prediction of DEGs from SGAs in terms of overall
performance: F1 score and accuracy (Table 1: 5th to last rows).
3.2. Gene embeddings compactly represent the functional impact of SGAs
We examined whether the gene embeddings capture the functional similarity of SGAs, using
mainly two metrics: NN accuracy and GO enrichment (Defined in SI Sec. S4). NN accuracy:
By capturing the co-occurrence pattern of somatic alterations, the Gene2Vec pre-trained gene
embeddings improve 36% in NN accuracy over the random chance of any pair of the genes
sharing Gene Ontology (GO) annotation15 (Table 2). The fine-tuned embeddings by GIT
further show a one-fold increase in NN accuracy. These results indicate that the learned
gene embeddings are consistent with the gene functions, and they map the discrete binary
SGA representation into a meaningful and compact space. GO enrichment: We performed
clustering analysis of SGAs in embedding space using k -means clustering, and calculated GO
enrichment, and we varied the number of clusters (k) to derive clusters with different degrees
of granularity (Fig. 2a). As one can see, when the genes are randomly distributed in the
embedding space, they get GO enrichment of 1. However, in the gene embedding space, the
GO enrichment increases fast until the number of clusters reaches 40, indicating a strong
correlation between the clusters in embedding space and the functions of the genes.
Table 2. NN accuracy with respect to GO in dif-
ferent gene embedding spaces.
Gene embeddings NN accuracy Improvement
Random pairs 5.3±0.36 –
Gene2Vec 7.2 36%
Gene2Vec + GIT 10.7 100%
To visualize the manifold of gene embed-
dings, we grouped the genes into 40 clusters,
and conducted the t-SNE31 of genes (Fig. 2b
left panel). Using PANTHER GO enrichment
analysis,32 12 out of 40 clusters are shown to be
enriched in at least one biological process (SI
Sec. S6). Most of the gene clusters are well-
defined and tight located in the projected t-
SNE space. As a case study, we took a close
look at one cluster (Fig. 2b right panel), which contains a set of functionally similar genes,
such as that code a protein family of type I interferons (IFNs), which are responsible for
immune and viral response.33
3.3. Self-attention reveals impactful SGAs on cancer cell transcriptome
Table 3. Top five SGA-affected genes ranked according to attention weight.
Rank PANCAN BRCA HNSC LUAD GBM BLCA
1 TP53 TP53 TP53 STK11 TP53 TP53
2 PIK3CA PIK3CACASP8 TP53 PTEN FGFR3
3 RB1 CDH1 PIK3CAKRAS C9orf53 RB1
4 PBRM1 GATA3 CYLD CYLC2 RB1 HSP90AA1
5 PTEN MED24 RB1 KEAP1 CHIC2 STAG2
While it is widely ac-
cepted that cancer is
mainly caused by SGAs,
but not all SGAs ob-
served in a cancer cell
are causative.1 Previous
methods mainly con-
centrate on searching
for SGAs with higher
than expected frequency to differentiate candidate drivers SGAs from passenger SGAs. GIT
provides a novel perspective to address the problem: identifying the SGAs that have a func-
tional impact on cellular signaling systems and eventually lead DEGs as the tumor-specific
candidate drivers. Here we compare the relationship of overall attention weights (inferred by
GIT model) and the frequencies of somatic alterations (used as the benchmark/control group)
in all the cancer types (Pan-Cancer) from our test data (Fig. 2c). In general, the attention
weights are correlated with the alteration frequencies of genes, e.g., common cancer drivers
such as TP53 and PIK3CA are the top two SGAs selected by both methods.2 However, our
self-attention mechanism assigns high weights to many of genes previously not designated
as drivers, indicating these genes are potential cancer drivers although their roles in cancer
development remain to be further studied. Table 3 lists top SGAs ranked according to GIT
attention weights in pan-cancer and five selected cancer types, where known cancer drivers
from TumorPortal3 and IntOGen34 are marked as bold font. Apart from TP53 and PIK3CA
(a)
p=0.017
(c) (d) (e)
p=5.1x10-8
CI=0.795
(b)
Fig. 3. (a) t-SNE of full tumor embedding et. (b) t-SNE of stratified tumor embedding (et-es).
(c) PCA of tumor embedding shows internal subtype structure of BRCA tumors. Color lablels the
group index of k -means clustering. (d) KM estimators of the three breast cancer groups. (e) Cox
regression using tumor embeddings.
as drivers in the pan-cancer analysis,2 we also find the top cancer drivers in specific cancer
types consistent with our knowledge of cancer oncology. For example, CDH1 and GATA3 are
drivers of breast invasive carcinoma (BRCA),35 CASP8 is known driver of head and neck
squamous cell carcinoma (HNSC),36 STK11, KRAS, KEAP1 are known drivers of lung ade-
nocarcinoma (LUAD),37 PTEN and RB1 are drivers of glioblastoma (GBM),38 and FGFR3,
RB1, HSP90AA1, STAG2 are known drivers in urothelial bladder carcinoma (BLCA).39 In
contrast, the most frequently mutated genes (control group) are quite different from that us-
ing attention mechanism (experiment group), and only a few of them are known drivers (SI
Sec. S7).
3.4. Personalized tumor embeddings reveal distinct survival profiles
Besides learning the specific biological function impact of SGAs on DEGs, we further examined
the utility of tumor embeddings et in two perspectives: (1) Discovering patterns of tumors
potentially sharing common disease mechanisms across different cancer types; (2) Using tumor
embedding to predict patient survival.
We first used the t-SNE plot of tumor embeddings to illustrate the common disease mech-
anisms across different cancer types (Fig. 3a). When cancer type embedding es is included in
full tumor embedding et, which has a much higher weight than any individual gene embed-
ding (Fig. 1b, Eq. 1) and dominates the full tumor embedding, tumor samples are clustered
according to cancer types. This is not surprising as it is well appreciated that expressions of
many genes are tissue-specific.40 To examine the pure effect of SGAs on tumor embedding, we
removed the effect of tissue by subtracting cancer type embeddings es, followed by clustering
tumors in the stratified tumor embedding space (Fig. 3b). It is interesting to see that each
dense area (potential tumor clusters) includes tumors from different tissues of origins, indi-
cating SGAs in these tumors may reflect shared disease mechanisms (pathway perturbations)
among tumors, warranting further investigations.
The second set of experiments was to test whether differences in tumor embeddings
(thereby difference in disease mechanisms) are predictive of patient clinical outcomes. We
conducted unsupervised k -means clustering using only breast cancer tumors from our test set,
which reveals 3 three groups (Fig. 3c) with significant difference in survival profiles evaluated
by log-rank test41 (Fig. 3d; p-value=0.017). In addition, using tumor embeddings as input fea-
tures, we trained `1,2-regularized (elastic net)42 Cox proportional hazard models43 in a 10-fold
cross-validation (CV) experiment. This led to an informative ranked list of tumors according
to predicted survivals/hazards evaluated by the concordance index (CI) value (CI=0.795), in-
dicating that the trained model is very accurate. We further split test samples into two groups
divided by the median of predicted survivals/hazards, which also yields significant separation
of patients in survival profiles (Fig. 3e; p-value=5.1× 10−8), indicating that our algorithm has
correctly ranked the patients according to characteristics of the tumor.
As shown above, distinct SGAs may share similar embeddings if they share similar func-
tional impact. Thus, two tumors may have similar tumor embeddings even though they do
not share any SGAs, as long as the functional impact of distinct SGAs from these tumors are
similar. Therefore, tumor embedding makes it easier to discover common disease mechanisms
and their impact on patient survival. To further test this, we also performed clustering analysis
on breast cancer tumors represented in original SGA space, followed similar survival analysis
as described in the previous paragraph (SI Sec. S8).
3.5. Tumor embeddings are predictive of drug responses of cancer cell lines
Raw SGAs Tumor embeddings
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Fig. 4. ROC curves and the
areas under the curve (AUCs)
of Lasso models trained with
original SGAs and tumor em-
beddings representations on pre-
dicting responses to four drugs.
Precision oncology concentrates on using patient-specific
omics data to determine optimal therapies for a patient.
We set out to see if SGA data of cancer cells can be used to
predict their sensitivity to anti-cancer drugs. We used the
CCLE dataset,44 which performed drug sensitivity screen-
ing over hundreds of cancer cell lines and 24 anti-cancer
drugs. The study collects genomic and transcriptomic data
of these cell lines, but in general, the genomic data (except
the molecularly targeted genes) from a cell line are not suf-
ficient to predict sensitivity its sensitivity to different drugs.
We discretized the response of each drug following the
procedure in previous research.44,45 Since CCLE only con-
tains a small subset of mutations in TCGA dataset (around
1,600 gene mutations), we retrained the GIT with this lim-
ited set of SGAs in TCGA, using default hyperparameters
we set before. Cancer type input was removed as well, which
is not explicitly provided in CCLE dataset. The output of
tumor embeddings et was then extracted as feature. We for-
mulated drug response prediction as a binary classification
problem with `1-regularized cross entropy loss (Lasso), where the input can be raw sparse
SGAs or tanh-curved tumor embeddings tanh(et). Following previous work,44 we performed
10-fold CV experiment training Lasso using either inputs to test the drug response prediction
task of four drugs with distinct targets. Lasso regression using tumor embeddings consistently
outperforms the models trained with original SGAs as inputs (Fig. 4). Specifically, in the case
of Sorafenib, the raw mutations just give random prediction results, while the tumor embed-
ding is able to give predictable results. It should be noted that it is possible that certain
cancer cells may host SGAs along the pathways related to FGFR, RAF, EGFR, and RTK,
rendering them sensitive to the above drugs. Such information can be implicitly captured and
represented by the tumor embeddings, so that the information from raw SGAs are captured
and pooled to enhance classification accuracy.
4. Conclusion and Future Work
Despite the significant advances in cancer biology, it remains a challenge to reveal disease
mechanisms of each individual tumor, particularly which and how SGAs in a cancer cell
lead to the development of cancer. Here we propose the GIT model to learn the general
impact of SGAs, in the form of gene embeddings, and to precisely portray their effects on the
downstream DEGs with higher accuracy. With the supervision of DEGs, we can further assess
the importance of an SGA using multi-head self-attention mechanisms in each individual
tumor. More importantly, while the tumor embeddings are trained with predicting DEGs
as the task, it contains information for predicting other phenotypes of cancer cells, such as
patient survival and cancer cell drug sensitivity. The key advantage of transforming SGA into
a gene embedding space is that it enables the detection and representation of the functional
impact of SGAs on cellular processes, which in turn enables detection of common disease
mechanisms of tumors even if they host different SGAs. We anticipate that GIT, or other
future models like it, can be applied broadly to gain mechanistic insights of how genomic
alterations (or other perturbations) lead to specific phenotypes, thus providing a general tool
to connect genome to phenome in different biological fields and genetic diseases. One should
also be careful that despite the correlation of genomic alterations and phenotypes such as
survival profiles and drug response, the model may not fully reveal the causalities and there
may exist other confounding factors not considered.
There are a few future directions for further improving the GIT model. First of all, decades
of biomedical research has accumulated a rich body of knowledge, e.g., Gene Ontology and
gene regulatory networks, which may be incorporated as the prior of the model to boost
the performance.46 Secondly, we expect that by getting a larger corpus of tumor data with
mutations and gene expressions, we will be able to train better models to minimize potential
overfitting or variance. Lastly, more clinically oriented investigations are warranted to examine,
when trained with a large volume of tumor omics data, the learned embeddings of SGAs and
tumors may be applied to predict sensitivity or resistance to anti-cancer drugs based SGA
data that are becoming readily available in contemporary oncology practice.
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Supplementary information
S1. Data pre-processing of SGAs and DEGs
We obtained SGA data, including SMs and SCNAs of 4,468 tumors consisting of 16 cancer
typesa directly from TCGA portal22 and Firehose browser of the Broad Instituteb. For SMs: We
considered all the non-synonymous mutation events of all genes and considered the mutation
events at the gene level, where a mutated gene is defined as one that contains one or more
non-synonymous mutations or indels. For SCNAs: TCGA network discretizes the gene SCNA
into 5 different levels: homozygous deletion, single copy deletion, diploid normal copy, low
copy number amplification, and high copy number amplification. We only included genes
with homozygous deletion (potentially significant loss of gene function) or high copy number
amplification (potentially significant gain of gene function) for further analysis, and filtered
out the other three types of not-so-significant SCNAs. Therefore, we collectively designated all
SGAs affecting a gene using the name of the gene being perturbed. Note that the preprocessing
step of SMs and SCNAs excluded the obvious tumor passenger SGAs, since the functions of
these mutated genes are not or only slightly perturbed. The remaining SGAs have the potential
of being cancer drivers, such as oncogenes with gained functions, or tumor suppressor genes
with lost functions. After processing genomic data from TCGA, we used a binary variable
in a “one-hot” vector to indicate the genomic status of a gene. For example, we represented
the genomic status of TP53 as 1, if it is perturbed by one or more of SM/SCNA events in a
tumor.
Gene expression data were pre-processed and obtained from the Firehose browser of the
Broad Institute. We determined whether a gene is differentially expressed in a tumor by
comparing the gene’s expression in the tumor against a distribution of the expression values
of the gene in the corresponding tissue-specific “normal” or control samples. For a given cancer
type, assuming the expression of each gene (log 2 based) follows a Gaussian distribution in
control sample, we calculated the p-values by determining the probability of observing an
expression value from control distribution. Following the practice in previous work,16 if the
p-value is equal or smaller than 0.005, the gene is considered as differentially expressed in the
corresponding tumor. However, if a DEG is associated with an SCNA event affecting it, we
remove it from the DEG list of the tumor.
aInstead of single cancer types, we used all the available samples of various cancer types, to find the
common signaling mechanisms SGAs in cancer. In addition, the GIT model benefits from the large
scale dataset. The heterogeneity of different cancer types was stratified by the additional cancer type
feature as input to the model.
bhttp://gdac.broadinstitute.org/
S2. Gene2Vec algorithm implementation
While gene embeddings can be directly learned using the GIT model, it has been shown in the
field of NLP that the pre-trained word embeddings can significantly improve the performance
in other related NLP tasks.12,14 Such pre-trained word embeddings can capture the knowledge
of co-occurrence pattern of the words in languages and exhibit sound semantic properties:
words of similar semantic meanings are close in embedding space, e.g., e“each” ≈ e“every”. We
therefore propose an algorithm called “Gene2Vec” to pre-train the gene embeddings, which is
closely related the skip gram word2vec12 pre-training algorithm. The biology rationale behind
Gene2Vec algorithm is that we are able to portrait the co-occurrence pattern of SGAs in
each tumor, i.e., mutually exclusive mutations,26 using gene embeddings and gene context
embeddings.
Given the gene embedding eg of an SGA-affected gene g and context embedding of any
possible SGA-affected gene c′: V = {vc′}c′∈G, where G is the set of all possible SGA-affected
genes, the skip gram paradigm assumes the probability that an alteration in gene c happens
together with the alteration in gene g within a tumor with probability:
Pr (c ∈ Context(g) | g) = exp (e
ᵀ
gvc)∑
c′∈G exp (e
ᵀ
gvc′)
. (S1)
We used the negative sampling (NS) technique to approximately maximize the log-
likelihood of skip gram, which would otherwise be computationally expensive to optimize
if directly following Eq. (S1). Algorithm 1 shows implementation of Gene2Vec.
Data: Genomic alterations in each tumor: T = {Ti={gi1, gi2, ..., gim(i)}}i=1,2,...,N .
Result: Pretrained gene embedding of each gene:
E = {eg ∈ Rn} g∈G .
Context gene embeddings:
V = {vg ∈ Rn} g∈G .
f(g)← 1Z
∑N
i=1 1(g ∈ Ti), g ∈ G; // Gene frequency
fn(g)← 1Zn f(g)3/4, g ∈ G; // Normalized frequency
eg ∼ U
(−0.5n , 0.5n )n , vg ← 0n, g ∈ G; // Initialize gene embeddings and context
embeddings
while not converges do
l← 0; // Total loss of a mini-batch samples
for b = 1, 2, ..., batch size do
g ∼ f ; // Sample a gene
gc ∼ Context(g ; T ); // Sample a context gene
gnr ∼ fn, r = 1, 2, ..., R ; // Sample negative context genes
l← l + NSLoss (g, gc, {gnr}Rr=1 ; E ,V) ; // Update
end
(E ,V)← (E ,V)− η · ∂l∂(E,V) ; // Gradient descent
end
Function Context(g ; T )
Pc ← U ({gc | gc ∈ Ti, g ∈ Ti}i=1,2,...,N ) ; // Uniform distribution on sequence of
adjacent mutations
return Pc
Function NSLoss(g, gc, {gnr}Rr=1 ; E ,V)
l← log σ (eᵀgvgc) +
∑R
r=1 log σ (−eᵀgvgnr); // Negative sampling loss of one sample
return l
Algorithm 1: Gene2Vec algorithm to pre-train the gene embeddings using skip
gram with negative sampling loss. Given the context information of somatic genomic
alterations (SGAs) in each cancer patient, i.e., whether two SGAs happened together in
a single tumor, we pre-trained the gene embeddings (and context gene embeddings) using
similar techniques to word2vec. Skip gram was used to predict the probability of co-occurred
SGAs c given a known SGA g, as explained in Equation S1. Negative sampling loss was uti-
lized to accelerate the maximization of log-likelihood in the skip gram assumption. Instead of
original mutation frequency f(g), the negative sampling frequency of SGA was sub-sampled
by scaling to f(g)3/4. In practice, the step size η in mini-batch gradient descent was decayed
after training for every epoch to converge fast and prevent overfitting. Note that E here is
defined slightly different from that in the main context, which contains both gene and cancer
type embeddings.
S3. Mathematical details of multi-head self-attention mechanism
For all SGA-affected genes {g}mg=1 and the cancer type s of a tumor t, we first mapped them
to corresponding gene embeddings {eg}mg=1 and a cancer type embedding es from a look-up
table E={eg}g∈G ∩ {es}s∈S , where eg and es are real-valued vectors. From the implementation
perspective, we treated cancer types in the same way as SGAs, except the attention weight of
it is fixed to be “1”.
The overall idea of producing the tumor embedding et is to use the weighted sum of cancer
type embedding es and gene embeddings {eg}mg=1 (Fig. 1b) :
et = 1 · es +
∑
g
αg · eg = 1 · es + α1 · e1 + ...+ αm · em. (S2)
The attention weights {αg}mg=1 are calculated by employing multi-head self-attention mech-
anism, using gene embeddings of SGAs {eg}mg=1 in the tumor (Fig. 1c):
α1, α2, ..., αm = FunctionAttention(e1, e2, ..., em). (S3)
The attention function FunctionAttention is implemented as a sub-network. In the case of single-
head attention, there is only one single head parameter θj, and the unnormalized weights
{βg,j}mg=1 can be derived as follows:
βg,j = θ
ᵀ
j · tanh(W0 · eg), g = 1, 2, ...,m, (S4)
which are further normalized to single-head weights {αg,j}mg=1:
α1,j , α2,j , ..., αm,j = softmax(β1,j , β2,j , ..., βm,j), (S5)
where softmax function is defined as : αg = exp (βg)/
∑m
g′=1 exp (βg′). In the case of multi-head
attention, there exist h different parameters Θ = {θj}hj=1. Then multiple attention weights of
each gene embedding are generated following Eq. (S4,S5) and summed up to be the final
multi-head attention weight:
αg =
∑h
j=1
αg,j = αg,1 + αg,2 + ...+ αg,h, g = 1, 2, ...,m. (S6)
S4. Evaluation metrics of gene embedding space
We designed two metrics for evaluating whether the gene embedding space is fair using the
Gene Ontology (GO).15 We mainly concentrated on evaluating whether SGA-affected genes
share GO annotations in the “biological process” domain, based on the assumption that genes
involved in a common biological process will likely share common functional impact. The top
1,474 frequently altered genes (affected by SGAs for more than 150 times across all the tumors
in the dataset) were used for evaluation, assuming that the gene embeddings of rare SGAs
may not be well learned.
NN accuracy: We first designed a metric called “nearest neighborhood (NN) accuracy”
as a measure of functional similarity among genes sharing similar gene embedding. It is defined
as the expectation of whether a pair of genes (g, c) that are nearest neighbors in the embedding
space share at least one same GO term:
NN accuracy = Eec∈NN(eg) [1 (GO(g) ∩GO(c) 6= ∅)] , (S7)
where 1(statement) is the indicator function; GO(g) the set of GO terms assigned to gene g;
NN(eg) the set of nearest neighbors of eg. The expectation E is approximated by iterating over
all possible pairs of genes. The higher NN accuracy, the functionally similar genes are more
close to each other in the embedding space.
GO enrichment: Apart from the NN accuracy, which only reflects the functional simi-
larities between two adjacent genes in embedding space, we also evaluated whether a cluster
of genes close in an embedding space share GO annotations through “GO enrichment”, which
is defined as:
enrichment =
EClust(eg)=Clust(ec) [1(GO(g) ∩GO(c) 6= ∅)]
Eg,c∈G [1(GO(g) ∩GO(c) 6= ∅)] , (S8)
where Clust(g) is the cluster that gene g belongs to. GO enrichment considers the functional
similarities of genes that are close in the embedding space. The larger it is, the higher correlated
are the GO functions and clusters (and it equals to 1 in random case).
S5. Performance of GIT on real and shuffled data
We plotted both F1 score and accuracy on the test set as the function of trained epochs
(Figure S1 “real data”), which indicate that the model gains the capability of predicting
DEGs as training proceeds, and finally reaches a stable state.
In order to validate that GIT is able to extract real statistical relationships between SGAs
and DEGs, we randomly shuffled the positions of DEGs in the DEG vector of a tumor, i.e.,
randomly relabel DEG names, and then trained a GIT to predict DEGs from SGAs. We
compared the performance of models trained with random datasets, by plotting F1 score and
accuracy during the training of the models (Figure S1 “shuffled data”). Note that, since most
DEGs in the data are zeros, a trivial solution is to call every DEG as 0, which can also achieve
good overall accuracy and minimize loss, but that will result in a low F1 because of low recall.
Indeed, the test F1 score in the DEG-permutation case drops to a very low value due to the
same reason.
(a) (b)
Fig. S1. The change of F1 score and accuracy on the test set as GIT trains on real
data or DEG-permuted data.
S6. Enriched functions of gene clusters
See Table S1 for the enriched functions of gene clusters. Fisher’s exact test with Bonferroni
correction (p-value<0.05) was implemented on genes that belong to 40 clusters. 12 clusters of
genes show to be significantly involved in at least one biological process. The genes in cluster
14, referred to as “IFN pathway”, was further analyzed as a case study in Sec. 3.2, which is
involved in viral defense response, immune response and cell surface signaling.
Table S1. Enriched gene ontologies in the “biological process” domain of human beings
(Homo sapiens).
Cluster ID Enriched gene ontology Enriched biological process p-value
2 GO:0038003 Opioid receptor signaling pathway 2.09e-02
3 GO:0050911 Detection of chemical stimulus involved in sensory perception of smell 3.16e-31
GO:0007186 G protein-coupled receptor signaling pathway 5.27e-21
4 GO:0007156 Homophilic cell adhesion via plasma membrane adhesion molecules 5.26e-03
GO:0001568 Blood vessel development 4.64e-02
GO:0048666 Neuron development 4.02e-02
GO:0009653 Anatomical structure morphogenesis 3.17e-04
8 GO:0045995 Regulation of embryonic development 3.77e-02
GO:0007155 Cell adhesion 4.28e-02
14 (IFN pathway) GO:0033141 Positive regulation of peptidyl-serine phosphorylation of stat protein 9.07e-30
GO:0002323 Natural killer cell activation involved in immune response 6.02e-29
GO:0042100 B cell proliferation 1.65e-26
GO:0043330 Response to exogenous dsrna 1.05e-25
GO:0002286 T cell activation involved in immune response 2.22e-24
GO:0060337 Type i interferon signaling pathway 2.93e-21
GO:0030183 B cell differentiation 1.40e-21
GO:0051607 Defense response to virus 2.85e-18
GO:0007596 Blood coagulation 5.77e-14
GO:0006959 Humoral immune response 4.82e-15
GO:0002250 Adaptive immune response 1.61e-12
GO:0010469 Regulation of signaling receptor activity 2.83e-12
16 GO:0050727 Regulation of inflammatory response 4.13e-02
23 GO:0003272 Endocardial cushion formation 3.61e-02
GO:0003179 Heart valve morphogenesis 9.79e-03
GO:0007156 Homophilic cell adhesion via plasma membrane adhesion molecules 4.87e-02
GO:0035295 Tube development 2.32e-03
GO:0051960 Regulation of nervous system development 4.73e-02
GO:0007399 Nervous system development 1.88e-02
25 GO:0051179 Localization 1.19e-02
30 GO:0000904 Cell morphogenesis involved in differentiation 4.15e-02
GO:0007155 Cell adhesion 2.93e-02
GO:0007275 Multicellular organism development 2.21e-03
35 GO:0007156 Homophilic cell adhesion via plasma membrane adhesion molecules 1.60e-09
36 GO:0040011 Locomotion 3.42e-02
40 GO:0035589 G protein-coupled purinergic nucleotide receptor signaling pathway 4.50e-03
S7. Top genes by attention mechanism and mutation rates
See Table S2 for the full list of top 100 genes that are assigned by the attention mechanism.
Table S3 shows the top 5 genes that are most frequently mutated in both pan-cancer and
single cancer types. It serves as the control group, in comparison to the attention mechanism
results (Table 3,S2; experiment group).
Table S2. List of candidate drivers whose corresponding SGAs have top 100 highest
attention weights. Boldfaced genes are known drivers according to TumorPortal3 and IntOGen34
database.
Rank Gene Rank Gene Rank Gene Rank Gene
1 TP53 26 MUC5B 51 KRTAP4-11 76 CNTNAP3B
2 PIK3CA 27 LMTK3 52 CYP4F11 77 NKRF
3 RB1 28 AHNAK 53 EP400 78 SETD2
4 PBRM1 29 VHL 54 XRN1 79 LAMA2
5 PTEN 30 FGFR3 55 MBD6 80 AARS
6 CDH1 31 PHF20 56 AR 81 SPON1
7 CASP8 32 STK11 57 ANKRD30BP2 82 WRN
8 KRAS 33 OCA2 58 PRICKLE2 83 LHX1
9 SLC1A6 34 GATA3 59 RGAG1 84 STAG2
10 POMC 35 PCNX 60 KRT23 85 KSR1
11 RRN3P2 36 KRTAP4-9 61 UGT1A1 86 GCDH
12 TFAM 37 LRRIQ3 62 PARP8 87 E2F3
13 CD163 38 MRGPRF 63 TMPRSS6 88 PDHX
14 WDFY3 39 HSP90AA1 64 FMN2 89 CLUH
15 WDR44 40 CNTN3 65 CDKN2A 90 PRICKLE4
16 CYP51A1 41 WNK3 66 DIP2B 91 GLUD2
17 ADARB2 42 PTPRD 67 TBP 92 CROCC
18 C9orf53 43 PCDHB16 68 ZNF624 93 IDH1
19 BAP1 44 RPLP0P2 69 FEM1B 94 GRIA1
20 TMPRSS13 45 COL6A1 70 CDKN2B 95 DLG5
21 SV2C 46 TTC39B 71 PDE4D 96 SMURF2P1
22 MYCBP2 47 PGR 72 ISLR2 97 CACNA1C
23 MED24 48 TBC1D4 73 FLRT3 98 KIAA1377
24 CYLD 49 ANKRD36C 74 ZFAT 99 PTPRZ1
25 CYLC2 50 GPATCH8 75 SMARCA4 100 PCSK5
Table S3. Top five SGA-affected genes for Pan-Cancer and a few selected
cancer types, ranked according to alteration frequency, as the control
group to GIT. The corresponding experiment group, which is the selected candi-
date drivers of GIT model, is shown in Table 3. The known cancer drivers according
to TumorPortal3 and IntOGen34 are marked in bold font.
Rank PANCAN BRCA HNSC LUAD GBM BLCA
1 TP53 TP53 TP53 TTN CDKN2A TTN
2 TTN PIK3CA CDKN2A TP53 CDKN2B TP53
3 PIK3CA TTN TTN CSMD3 C9orf53 ARID1A
4 CSMD3 POU5F1B PIK3CA PCDHAC2 EGFR DNAH5
5 MUC4 TRPS1 LINC00969 MUC16 MTAP CDKN2A
S8. Survival analysis based on raw SGAs
SGAs alone as tumor representations are not informative of predicting survival profiles. See
Fig. S2 for survival analysis based on raw SGAs.
p=0.37
(a) (b) (c)
p=0.0060
CI=0.617
Fig. S2. (a) PCA plot showing k -means clustering of BRCA tumors using their SGA vectors. Most
tumors merge around the origin (Cluster 1; with a small number of SGAs), while others (Cluster
2,3; with a large number of SGAs) are outliers and far away from the origin. (b) KM estimators and
log-rank test on the three BRCA tumor groups in the SGA space. (c) Cox regression using SGAs
(top mutated 474 genes are used).
